Catheter-related Bloodstream Infection (CRBSI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Catheter-related bloodstream infection
(CRBSI) refers to the presence of bacteremia originating from an intravenous
catheter. It is a common, severe, and expensive complication of central venous
catheterization and is the leading cause of nosocomial bacteremia.
Intravascular catheters are vital in modern medical practices, being used in
critically ill patients for various purposes such as administering fluids,
blood products, medication, nutritional solutions, and monitoring hemodynamics.
Among all medical devices, central venous catheters (CVCs) carry the highest
risk of device-related infections and contribute significantly to morbidity and
mortality. They are also the primary source of bacteremia and septicemia in
hospitalized patients. Several potential risk factors contribute to the
development of CRBSI, including underlying diseases, method and site of
catheter insertion, duration of catheterization, and the purpose of
catheterization. The use of intravascular catheters for parenteral nutrition
increases the risk of CRBSI. The catheter itself can be involved in four
different pathways leading to infection: colonization of the catheter tip and
cutaneous tract by skin flora, colonization of the catheter lumen due to
contamination, hematogenous seeding of the catheter from another infected site,
and contamination of the catheter lumen with infusate. Gram-positive pathogens
accounted for 64% of CRBSI cases, while Gram-negative pathogens accounted for
36%. The most common pathogens causing CRBSI were Staphylococcus aureus (40%),
Pseudomonas aeruginosa (16%), coagulase-negative staphylococci (8%),
Escherichia coli (8%), Klebsiella pneumoniae (8%), and Acinetobacter baumannii
(4%). The choice of initial antibiotics for treating CRBSI depends on the
severity of the patient's clinical condition, risk factors for infection, and
the likely pathogens associated with the specific intravascular device.
·
In the USA, the incidence of Catheter-Related
Bloodstream Infections (CRBSI) ranges from 0.05 to 6.8 infections per 1000
catheter days.
Thelansis’s “Catheter-related
Bloodstream Infection (CRBSI) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2022 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Catheter-related
Bloodstream Infection (CRBSI) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Catheter-related Bloodstream Infection (CRBSI) across 8 MM market from the
centre of Excellence/ Public/ Private hospitals participated in the study.
Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Catheter-related Bloodstream Infection
(CRBSI) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment